Craft

Medtronic Summary

Overview

Medtronic is a global company that develops, manufactures, distributes, and sells device-based medical therapies and services. Its products include pacemakers, insertable cardiac monitors, implantable defibrillators, leads and delivery systems, ablation products, electrophysiology catheters, coronary and peripheral stents and related delivery systems, therapies for uncontrolled hypertension, endovascular stent graft systems, heart valve replacement technologies, and cardiac tissue ablation systems, as well as image-guided surgery and intra-operative imaging systems. The company primarily serves hospitals, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations (GPOs).

TypePublic
Founded1949
HQMinneapolis, MN, USMap
Websitemedtronic.com
Employee Ratings
3.9
More
Overall CultureBMore

Locations

Medtronic is headquartered in
Minneapolis, United States

Location Map

Latest Updates

Company Growth (employees)

Employees (est.) (Apr 2020)90,000
Job Openings2
Website Visits (Dec 2020)3 m(-13%)
Revenue (FY, 2020)$28.9 B(-5%)
Share Price (Jan 2021)$116.8
Cybersecurity ratingCMore

Key People/Management at Medtronic

Medtronic Office Locations

Medtronic has offices in Minneapolis, Boulder, Doral, Fridley and in 70 other locations

Medtronic Financials and Metrics

Medtronic Revenue

Medtronic's revenue was reported to be $28.91 b in FY, 2020 which is a 5.4% decrease from the previous period.

USD

Revenue (Q2, 2021)$7.65 b
Gross profit (Q2, 2021)$4.94 b
Gross profit margin (Q2, 2021), %64.6%
Net income (Q2, 2021)$494 m
EBIT (Q2, 2021) $930 m
Market capitalization (15-Jan-2021)$157.23 b
Closing stock price(15-Jan-2021)$116.81
Cash (30-Oct-2020)$6.42 b
EV $180.82 b

Medtronic's current market capitalization is $157.2 b.

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020
Revenue28.8 b29.7 b30 b30.6 b28.9 b
Revenue growth, %42%3%1%2%(5%)
Cost of goods sold9.1 b9.3 b9.1 b9.2 b9.4 b
Gross profit19.7 b20.4 b20.9 b21.4 b19.5 b
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021
Revenue7.2 b7.3 b7.3 b7.4 b7.1 b7.4 b7.4 b7.5 b7.5 b7.5 b7.7 b7.7 b6.5 b7.6 b
Cost of goods sold2.3 b2.3 b2.3 b2.4 b2.1 b2.2 b2.2 b2.2 b2.3 b2.4 b2.4 b2.4 b2.5 b2.7 b
Gross profit4.9 b5 b5 b5 b4.9 b5.2 b5.2 b5.3 b5.3 b5.1 b5.3 b5.3 b4 b4.9 b
Gross profit Margin, %68%68%69%68%70%70%70%71%70%68%69%69%62%65%
show all

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020
Cash2.9 b5 b3.7 b4.4 b4.1 b
Accounts Receivable5.6 b5.6 b6 b6.2 b4.6 b
Inventories3.5 b3.3 b3.6 b3.8 b4.2 b
Current Assets23.6 b24.9 b23 b22 b22 b
show all

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020
Net Income3.5 b4 b3.1 b4.7 b4.8 b
Depreciation and Amortization2.8 b2.9 b2.6 b2.7 b2.7 b
Accounts Receivable(435 m)(75 m)(275 m)(581 m)1.3 b
Inventories(186 m)(227 m)(192 m)(274 m)(577 m)
show all

USD
Q2, 2021
EV/EBIT170.7 x
EV/CFO74.2 x
Financial Leverage1.9 x
  • Medtronic Market Cap History

  • Medtronic Stock Price

Revenue Breakdown

Medtronic revenue breakdown by business segment: 8.2% from Diabetes Group, 28.9% from Minimally Invasive Therapies Group, 36.2% from Cardiac and Vascular Group and 26.7% from Restorative Therapies Group

Medtronic revenue breakdown by geographic segment: 51.6% from United States, 32.1% from Non-U.S. Developed Markets and 16.3% from Emerging Markets

Medtronic Operating Metrics

Medtronic's Patients Served per Year was reported to be 72 m in FY, 2020.

FY, 2015FY, 2016FY, 2017FY, 2018Jun, 2019FY, 2019FY, 2020
Countries160160160150150150
Trademarks836
Patents and Patent Applications49 k
Patients Served per Year72 m

Medtronic Acquisitions / Subsidiaries

Company NameDateDeal Size
Titane SpineMay 10, 2019
EPIX TherapeuticsJanuary 24, 2019
NutrinoNovember 30, 2018
Mazor RoboticsSeptember 21, 2018$1.64 b
Visionsense LtdApril 11, 2018$75 m
CrosponDecember 10, 2017
HeartWare InternationalJune 27, 2016$1.1 b
Responsive OrthopedicsJune 07, 2016
Smith & Nephew's gynecology businessMay 18, 2016$350 m
BellcoFebruary 02, 2016

Human Capital Metrics

Source: SEC Filings FY 2015, SEC Filings FY 2015, SEC Filings FY 2015

Medtronic Hiring Categories

Medtronic Median Salaries

Source: 9 public H-1B filings from Medtronic

Medtronic Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Medtronic Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Medtronic Website Traffic

Alexa Website Rank

Total Visits per monthSimilarWeb

Medtronic Online and Social Media Presence

Twitter followers

75.89 k Twitter followers

6 Months

Medtronic has 75.89 k Twitter Followers. The number of followers has increased 0.18% month over month and increased 0.37% quarter over quarter.

Medtronic's Trends

Search term - Medtronic

Twitter Engagement Stats for @Medtronic

  • 4.51 k

    Tweets

  • 393

    Following

  • 75.89 k

    Followers

  • 44

    Tweets last 30 days

  • 7.8

    Avg. likes per Tweet

  • 52.3%

    Tweets with engagement

Medtronic Technology StackBuildWith Logo

  • ads

    18 products used

    • Adify
    • AdRoll
    • AppNexus
      • AppNexus Segment Pixel
      • Burst Media
      • Centro
      • Collective Media
      • DoubleClick.Net
      • Facebook Exchange FBX
      • Falk Realtime
      • Google Adsense
      • Google AdSense Custom Search Ads
      • Google Adsense for Search
      • IponWeb BidSwitch
      • Openads/OpenX
      • Pubmatic
      • Twitter Ads
      • Yahoo Small Business
  • analytics

    16 products used

    • Adobe Dynamic Tag Management
    • Adobe Target Standard
    • Dynatrace
      • Eloqua
      • ForeSee Results
      • Google Analytics
      • Google Analytics Classic
      • Google Analytics Event Tracking
      • Google Content Experiments
      • Google Website Optimizer
      • Omniture Adobe Test and Target
      • Omniture SiteCatalyst
      • Rapleaf
      • Twitter Analytics
      • Visual Website Optimizer
      • Yahoo Web Analytics
  • cdn

    8 products used

    • AJAX Libraries API
    • Akamai
    • CloudFront
      • Content Delivery Network
      • GStatic Google Static Content
      • OSS CDN
      • Twitter CDN
      • Yahoo Image CDN
  • cdns

    1 product used

    • Akamai Edge
Learn more on BuiltWith

Medtronic Company CultureCultureAndCompensation Logo

  • Overall Culture

    B

    70/100

  • CEO Rating

    A+

    81/100

  • Compensation

    A+

    80/100

  • Diversity

    B-

    68/100

Learn more on Comparably

Medtronic News and Updates

Jan 19, 2021
Worldwide Industry for Depth of Anesthesia Monitoring Devices Industry to 2030 - Featuring Medtronic, GE Healthcare & Nihon Kohden Among Others
DUBLIN, Jan. 19, 2021 /PRNewswire/ -- The "Depth of Anesthesia Monitoring Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering. This report on the global depth of anesthesia monitoring...
Jan 18, 2021
Insights on the Telemedicine Market and Services Global Market to 2027 - Players Include BioTelemetry, Medtronic & OBS Medical Among Others
DUBLIN, Jan. 18, 2021 /PRNewswire/ -- The "Telemedicine Market and Services - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report has been added to ResearchAndMarkets.com's offering. This report on the global Telemedicine market studies past as well as...
Jan 15, 2021
Global Dialysis Devices and Equipment Market Opportunities and Strategies to 2030 with Fresenius Medical Care, Baxter International, Nipro, B Braun Melsungen & Medtronic Dominating
Dublin, Jan. 15, 2021 (GLOBE NEWSWIRE) -- The "Dialysis Devices and Equipment Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering. The global dialysis devices and equipment reached a value of nearly $16,534.0 million in 2019, having increased at a compound annual growth rate (CAGR) of 3.1% since 2015. The market is expected to decline from $16,534.0 million in 2019 to $13,293.5 million in 2020 at a rate of -19.6%. The decline is mainly due to lockdown and social distancing norms imposed by various countries and economic slowdown across countries owing to the COVID-19 outbreak and the measures to contain it. The market is then expected to recover and grow at a CAGR of 8.7% from 2021 and reach $19,591.8 million in 2023. The market is expected to reach $21,939.9 million in 2025, and $29,010.8 million in 2030.Growth in the historic period resulted from rise in healthcare expenditure and rapid growth in elderly population. Factors that negatively affected growth in the historic period were low healthcare awareness and reimbursements. Going forward, increasing prevalence of chronic diseases, technological advancements and increasing home therapies will drive the growth. Factors that could hinder the growth of the dialysis devices and equipment in the future include COVID-19 pandemic and high cost of equipment and presence of alternative treatment.The dialysis devices and equipment is segmented by product into hemodialysis devices, peritoneal devices, consumables and continuous renal replacement therapy (CRRT). The consumables market was the largest segment of the dialysis devices and equipment segmented by product, accounting for 64.7% of the total in 2019. Going forward, the peritoneal dialysis devices segment is expected to be the fastest growing segment in the dialysis devices and equipment segmented by product, at a CAGR of 4.7% during 2019-2023. The dialysis devices and equipment is also segmented by end use into hospitals and clinics, home care settings and ambulatory surgical centers. The hospital and clinics market was the largest segment of the dialysis devices and equipment segmented by end use, accounting for 71.8% of the total in 2019. Going forward, the home care settings segment is expected to be the fastest growing segment in the dialysis devices and equipment market segmented by end use, at a CAGR of 4.6% during 2019-2023. North America was the largest region in the global dialysis devices and equipment, accounting for 34.5% of the total in 2019. It was followed by Asia-Pacific and Western Europe, and then the other regions. Going forward, the fastest-growing regions in the dialysis devices and equipment will be the Middle East, and Asia Pacific, where growth will be at CAGRs of 6.9% and 6.6% respectively. These will be followed by Eastern Europe, and the Africa, where the markets are expected to grow at CAGRs of 5.3% and 4.1% respectively.The global dialysis devices and equipment is concentrated, with a small number of large players in the market. The top ten competitors in the market made up to 59.0% of the total market in 2019. Major players in the market include Fresenius Medical Care AG And Co. KGaA, Baxter International, Nipro Corporation, B Braun Melsungen and Medtronic plc.The top opportunities in the dialysis devices and equipment segmented by product will arise in the consumables segment, which will gain $2,124.6 million of global annual sales by 2023. The top opportunities in the dialysis devices and equipment segmented by end user will arise in the hospitals and clinic segment, which will gain $2,162.9 million of global annual sales by 2023. The dialysis devices and equipment size will gain the most in China at $736.2 million. Market-trend-based strategies for the dialysis devices and equipment include focusing on developing peritoneal dialysis devices, expanding the product portfolio for homecare settings and focusing in acquisitions and mergers to expand the business. Player-adopted strategies in the dialysis devices and equipment include expanding through strategic acquisitions and expansion through the launch of new devices.Amidst the unprecedented outbreak of corona virus, governments across the world are advising people to stay indoors and practice social distancing, to reduce the spread of the pandemic. This has decreased short-term potential growth opportunities for the dialysis devices and equipment industry. Lockdown effected the transportation, access to health care facilities, availability of medicines and consumables as well as both inpatient and outpatient services. Increased surge in COVID-19 cases and increasing hospital expenditure towards emergency equipment led to decline in purchase activities of dialysis devices and equipment across the globe. This has resulted in short term decline in demand for dialysis devices and equipment. However, the COVID-19 infection can increase the risk of acute kidney injury can positively affect the dialysis devices and equipment market.To take advantage of the opportunities, the report recommends the dialysis devices and equipment companies to focus on disposable consumables, focus on peritoneal dialysis devices, home therapies, increasing merger and acquisition activity, expand in emerging markets, leverage e-commerce to maximize reach and revenues, provide competitively priced offerings in low-income countries to reach new users, premium pricing for advanced equipment, companies should focus on increasing healthcare awareness, participate in trade shows and events, and focus on individual customers.Key Topics Covered: 1. Dialysis Devices and Equipment Market Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure6. Introduction6.1.1. Segmentation by Geography6.1.2. Segmentation by Product6.1.3. Segmentation by End-User7. Dialysis Devices and Equipment Market Characteristics7.1. Market Definition7.2. Market Segmentation by Product7.2.1. Hemodialysis Devices7.2.2. Peritoneal Dialysis Devices7.2.3. Continuous Renal Replacement Therapy (CRRT) Systems7.2.4. Consumables7.3. Market Segmentation by End-User7.3.1. Hospitals and Clinics7.3.2. Ambulatory Surgical Centers7.3.3. Homecare Settings8. Dialysis Devices and Equipment Market Trends and Strategies8.1. Increasing Demand For Peritoneal Dialysis Devices8.2. Rising Importance of Home Therapies8.3. Increasing Merger and Acquisition Activity8.4. High Demand For Disposable Consumables9. COVID-19 Impact On The Dialysis Devices and Equipment Market9.1. Impact On Dialysis Devices Supply Chains and Production9.2. Home Dialysis Utilization - Increased Preference and Challenges9.3. COVID-19 Increases The Risk of Developing Acute Kidney Injury (AKI)10. Global Dialysis Devices and Equipment Market Size and Growth10.1. Market Size10.2. Historic Market Growth, 2015-2019, Value ($ Million)10.2.1. Drivers of The Market 2015-201910.2.2. Restraints On The Market 2015-201910.3. Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)10.3.1. Drivers of The Market 2019-202310.3.2. Restraints On The Market 2019-202311. Global Dialysis Devices and Equipment Market Segmentation11.1. Global Dialysis Devices and Equipment Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)11.1.1. Consumables11.1.2. Hemodialysis Devices11.1.3. Peritoneal Dialysis Devices11.1.4. Continuous Renal Replacement Therapy (CRRT) Systems11.2. Global Dialysis Devices and Equipment Market, Segmentation by End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)11.2.1. Hospitals and Clinics11.2.2. Home Care Settings11.2.3. Ambulatory Surgical Centers12. Dialysis Devices and Equipment Market, Regional and Country Analysis12.1. Global Dialysis Devices and Equipment Market, by Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)12.2. Global Dialysis Devices and Equipment Market, by Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million) Companies Mentioned
Jan 14, 2021
Outlook on the Surgical Instruments Global Market to 2025 - Featuring Medtronic, Ethicon and Aesculap Among Others
Dublin, Jan. 14, 2021 (GLOBE NEWSWIRE) -- The "Surgical Instruments Market (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. According to the findings of a study by the University of California, Irwin Medical Center, hip and knee replacement surgeries are on the rise owing to incrementing percentage of geriatrics and the mounting obesity rates in the US. Furthermore, the institute estimates that by 2030, the total number of knee replacements performed in the US will escalate by a whopping 600% as compared to that in 2005. Subsequently, there will be an upsurge in demand for the instruments needed for those surgeries, which will significantly stroke the prospects in the global surgical instruments market, which had a value of $10.2 billion to $11.5 in 2019. Furthermore, opportunities in the surgical instruments market will be mounting at healthy CAGR of 6% to 6.5% during the forecast period of 2020 to 2025.Apparently, the developed economy, growing awareness among the citizens, broad spectrum of patients, and the availability of multifunctional products owing to the world-class healthcare facilities in the North American countries are booming the surgical instruments market in the region. Conspicuously, the deep-pocket investors in the region find the healthcare sector as a compelling investment, which includes the investment in surgical instruments. This largely supports the surgical instruments market in North America, and according to the findings by the market analyst, the region held the maximum share of 39% to 43% in 2019. Surgical instruments are devices like scalpel and hemostat that perform functions pertaining to surgery by a surgical technologist that includes modifying a biological tissue. There are many types of surgical instruments ranging from clamps and occluders for blood vessels, retractors for skin and ribs, and stereotactic devices. The major surgical instruments marketplace are private and government hospitals where they are used to perform diverse kind of surgeries.Their application is segmented on the basis of the type of surgical instruments that include surgical sutures and staplers, handheld surgical devices, and electrosurgical devices. The key market application segment is in the surgical suture and staplers, which will grow with a CAGR of 35% to 37% through to 2025.The palpable rise in diseases such as obesity, cancer, and cardiovascular conditions coupled with the technological advancements and innovations in the healthcare sector to provide faster recoveries to the patients will catapult the demand for surgical sutures and staplers in the surgical instruments market, highlights the market analyst in the report. Surgical Instruments Market Research Scope: The base year of the study is 2020, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the surgical instruments market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the types of surgical instruments market, and their specific applications in cardiothoracic and others.Key Questions Addressed in the Surgical Instruments Market Report
Jan 12, 2021
Asia Scoliosis Management Market Size Worth USD 826.8 Million at 6.1% CAGR; Industry Giants Such as Medtronic and Zimmer Biomet to Bolster Productions Operations in Asia Pacific: Fortune Business Insights™
Key Prominent Players Covered in the Asia Scoliosis Management Market Research Report Are OTTOBOCK, NuVasive, Inc., Orthofix Holdings, Inc., DePuy Synthes Companies, DJO Global, Aspen Medical Products, LLC, Zimmer Biomet, Medtronic and other key market players. Key Prominent Players Covered in the Asia Scoliosis Management Market Research Report Are OTTOBOCK, NuVasive, Inc., Orthofix Holdings, Inc., DePuy Synthes Companies, DJO Global, Aspen Medical Products, LLC, Zimmer Biomet, Medtronic and other key market players.
Jan 11, 2021
Global Spinal Fusion Market Analysis and Forecast Model to 2030, Featuring Key Players Medtronic plc, NuVasive Inc, DePuy Synthes Inc, Globus Medical Inc and More
Dublin, Jan. 11, 2021 (GLOBE NEWSWIRE) -- The "Spinal Fusion (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering. The model discusses in detail the impact of COVID-19 on Spinal Fusion market for the year 2020 and beyond. Spinal fusion can be used to treat a wide variety of conditions that affect the spine. Spinal fusion decompresses and stabilizes the spine, including the lumbar, cervical, and thoracic regions. Common indications for spinal fusion include degenerative disc disease, spondylolisthesis, spinal stenosis, trauma, spinal tumours, and scoliosis. Lumbar fusions are the most common spinal fusion procedures performed. More than half of all patients undergoing spinal fusion are over the age of 50. America and Europe through the forecast period in favor of cementless and hybrid options.Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.Key Inclusions of the market model are - Currently marketed Spinal Fusion and evolving competitive landscape -

Medtronic Blogs

Jan 14, 2021
Medtronic Launches First-of-Its-Kind Adaptive Deep Brain Stimulation (aDBS) Trial in Parkinson's Disease Patients
Medtronic Launches First-of-Its-Kind Adaptive Deep Brain Stimulation (aDBS) Trial in Parkinson's Disease Patients Content Import Thu, 01/14/2021 - 08:31 Medtronic Launches First-of-Its-Kind Adaptive Deep Brain Stimulation (aDBS) Trial in Parkinson's Disease Patients January 14, 2021 at 8:30 AM EST This release is a backfill from a News Wire General ADAPT-PD Global Study Designed to Demonstrate Safety & Efficacy of Automated Therapy Which Responds to Brain Signals in Parkinson's Disease Patients DUBLIN, Jan. 14, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first enrollment in ADAPT-PD (Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease), its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson's Disease (PD). Adaptive deep brain stimulation is an investigational feature of the Percept™ PC device that could be enabled if approved. The investigational feature used in this study allows for automated adjustment of brain stimulation to provide therapy to manage symptoms of Parkinson's disease based on a patient's clinical state. The randomized study will take place across 12 study sites at leading Movement Disorders research centers in the United States, Europe, and Canada. An estimated 36 subjects will undergo a total evaluation period of 15 months. The primary endpoint of ADAPT-PD will compare standard continuous DBS (cDBS) to aDBS for hours of 'On' time without troublesome dyskinesias, a measure of treatment efficacy versus side effects, as reported by patient diary. Qualifying subjects in the study will receive cDBS at baseline followed by randomized evaluation of two different aDBS algorithms in a blinded manner. Dr. Helen Bronte-Stewart, the John E. Cahill Family Professor in the Department of Neurology and Neurological Sciences at Stanford University and who is the North American principal investigator for the ADAPT-PD study, enrolled the first patient at the Stanford Movement Disorders Center. Dr. Bronte-Stewart and her collaborators previously laid the foundation for ADAPT-PD by performing the first closed loop deep brain stimulation studies in Parkinson's disease using an investigational prototype research-only system (Activa™ PC+S-Nexus D3). ADAPT-PD represents an evolutionary leap from these early studies in that sensing of brain signals and automated adjustment of stimulation are performed by using unlocked investigational features of the commercially available Percept PC DBS device, allowing patients in the study to be both treated and measured while outside the clinic. According to the Parkinson's Foundation, more than 10 million people worldwide are living with Parkinson's disease and while similar, the progression of symptoms is often different from one patient to another due to the diversity of the disease. People with PD may experience tremor; slowness of movements (bradykinesia); limb rigidity; gait and balance challenges. DBS is a well-established, safe and effective therapy for the treatment of motor symptoms in PD, including tremor (shaking); slowed movement (bradykinesia); and stiffness (rigidity) when medications aren't as effective as they used to be. Opportunities exist to improve the efficacy of DBS therapy. Current commercially-approved DBS systems deliver stimulation continuously (cDBS) and are adjusted manually within physician-defined limits to optimize therapy for the patient. In contrast, aDBS therapy may individualize and optimize PD therapy for the same motor symptoms as with cDBS by automatically adjusting stimulation within physician-defined limits, based on brain signals detected by the DBS system. ADAPT-PD will be using the Percept PC DBS system with investigational aDBS feature. While the aDBS feature is investigational and has not been approved for commercial use, the Percept PC device (cDBS) was approved by the FDA in June 2020. The Percept PC device (cDBS) utilizes proprietary BrainSense™ technology making it the only DBS system with the ability to capture patient-specific brain signals. The sensing feature of the Percept PC system is intended for use in patients receiving DBS where chronically-recorded bioelectric data may provide useful, objective information regarding patient clinical status. Clinical benefits of brain sensing have not been established. "Percept PC was developed with a significant amount of capabilities built into its system. We see this technology evolving to deliver even more value over time. The recently initiated ADAPT-PD is the first trial to gather clinical evidence to unlock those capabilities," said Mike Daly, vice president and general manager of the Brain Modulation business, which is reported as part of the Restorative Therapies Group at Medtronic. "Additionally, stimulation adjusted based on patient need, aDBS, could reduce total power output and possibly extend the life of the device." Medtronic is a pioneer in DBS, developing a small, pacemaker-like device, placed under the skin of the chest or abdomen, to send electronic signals to an area in the brain that controls movement. DBS may help control movement symptoms associated with PD when medications are no longer as effective as they used to be. To date, more than 175,000 patients have been implanted with Medtronic DBS devices for management of Parkinson's symptoms and other conditions such as Essential Tremor, Epilepsy, Dystonia and OCD. "aDBS technology will allow DBS to be responsive in real-time, communicating with the patient's brain, as needed - which could reduce the amount of programming burden on a clinician," added Professor Andrea Kühn, head of Movement Disorders and Neuromodulation, Charité University Hospital, Berlin. Professor Kühn is one of the leading scientists on electrophysiological markers for PD and designers of the ADAPT study; her team at the Charité, Universitätsmedizin Berlin implanted the first Percept PC DBS patient in the world. About Medtronic DBS TherapyDBS therapy uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver electrical stimulation to precisely targeted areas of the brain as adjunctive treatment for several neurological disorders. Medtronic DBS systems were the first approved for full-body MRI scans under specific conditions in the United States. Since 1997, more than 175,000 Medtronic DBS devices have been implanted worldwide. DBS therapy is currently approved in many locations around the world, including the U.S. and Europe, for the treatment of disabling motor symptoms of recent and longer-standing Parkinson's disease, essential tremor, and epilepsy. The therapy is also approved in the U.S. under Humanitarian Device Exemption (HDE) to treat chronic intractable primary dystonia and severe, treatment-resistant obsessive-compulsive disorder. The FDA-approved indication for Parkinson's disease is as follows: Bilateral stimulation of the internal globus pallidus (GPi) or the subthalamic nucleus (STN) using Medtronic DBS Therapy for Parkinson's Disease is indicated for adjunctive therapy in reducing some of the symptoms in individuals with levodopa-responsive Parkinson's disease of at least 4 years' duration that are not adequately controlled with medication, including motor complications of recent onset (from 4 months to 3 years) or motor complications of longer-standing duration. About MedtronicMedtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. Contacts: David T. Young Ryan Weispfenning Public Relations Investor Relations +1-774-284-2746 +1-763-505-4626     View original content to download multimedia:http://www.prnewswire.com/news-releases/medtronic-launches-first-of-its-kind-adaptive-deep-brain-stimulation-adbs-trial-in-parkinsons-disease-patients-301207921.html SOURCE Medtronic plc ADAPT-PD Global Study Designed to Demonstrate Safety & Efficacy of Automated Therapy Which Responds to Brain Signals in Parkinson's Disease Patients DUBLIN , Jan. 14, 2021 /PRNewswire/ --  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first enrollment in
Dec 16, 2020
Medtronic Strengthens Leadership in Navigated, Robotic Spine Surgery with FDA Clearance of Midas Rex™ Drills and Navigated Disc Prep and Interbodies for U.S. with Mazor™ Robotic Guidance System
- The First Company to Offer Navigated Interbody, Disc Prep and High-Speed Drills Launches a New Integrated Robotic Solution - Broader Functionality Includes Enhanced Visualization of Tools, Greater Access and Interbody Navigation to Streamline Hospital Workflows DUBLIN , Dec.
Dec 14, 2020
Sean Salmon Named EVP & President Cardiovascular Portfolio; Continues as EVP & President Diabetes Operating Unit
DUBLIN , Dec. 14, 2020 /PRNewswire/ --  Medtronic plc (NYSE:MDT) announced today that Sean Salmon , Executive Vice President and President, Diabetes Operating Unit has been named Executive Vice President and President, Cardiovascular Portfolio effective January 1 .
Dec 08, 2020
Medtronic Launches the First and Only Pediatric and Neonatal Acute Dialysis Machine in the U.S.
The Carpediem™ system is designed to treat patients requiring renal replacement therapy weighing between 2.5 and 10 kilograms (5.5 to 22 pounds) DUBLIN , Dec. 8, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced the U.S. commercial launch of the Carpediem™ Cardio-Renal Pediatric

You may also be interested in Related companies

logo
Gala Therapeutics
HQ
Menlo Park, US
Employees
33  3increase
Gala Therapeutics is a medical device company developing technologies for the treatment of pulmonary diseases.
View company
logo
CorneaGen
HQ
Seattle, US
Employees
137  1increase
CorneaGen is a company that develops medical devices and therapies for the cornea.
View company
logo
Relievant Medsystems
HQ
Bloomington, US
Employees
57  6increase
Relievant Medsystems develops therapeutic solutions to treat chronic axial low back pain.
View company
logo
Varian Medical Systems
HQ
Palo Alto, US
Employees
10062  40increase
Varian Medical Systems is a manufacturer of medical devices and software for treating cancer and other medical conditions.
View company
When was Medtronic founded?
Medtronic was founded in 1949.
Who are Medtronic key executives?
Medtronic's key executives are Geoffrey S. Martha, Alex Gu and Brad Lerman.
How many employees does Medtronic have?
Medtronic has 90,000 employees.
What is Medtronic revenue?
Latest Medtronic annual revenue is $28.91 b.
What is Medtronic revenue per employee?
Latest Medtronic revenue per employee is $321.26 k.
Who are Medtronic competitors?
Competitors of Medtronic include Becton Dickinson, Cook Medical and Wright Medical.
Where is Medtronic headquarters?
Medtronic headquarters is located at 710 Medtronic Pkwy NE, Minneapolis.
Where are Medtronic offices?
Medtronic has offices in Minneapolis, Boulder, Doral, Fridley and 71 other locations
How many offices does Medtronic have?
Medtronic has 79 offices.

Craft real-time company insights

Learn about Craft real-time company insights

Receive alerts for 300+ data fields across thousands of companies

Footer menu